Triphasic blood pressure responses to cannabinoids: Do we understand the mechanism?

British Journal of Pharmacology

Volumn 165, Issue 7, 2012, Pages 2073-2088

  Malinowska, Barbara ^a   Baranowska Kuczko, Marta ^a   Schlicker, Eberhard ^b  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

9 tetrahydrocannabinol; anaesthetized rodents; anandamide; blood pressure response; cannabinoid CB 1 receptor; conscious rat; endothelial cannabinoid receptor; humans; vanilloid TRPV1 receptor; WIN55212 2

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; AM 3506; ANANDAMIDE; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CANNABIDIOL; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID DERIVATIVE; CAPSAICIN; CAPSAZEPINE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DEXANABINOL; ENDOCANNABINOID; ENDOVANILLOID N ARACHIDONOYL DOPAMINE; FATTY ACID AMIDASE INHIBITOR; METHANANDAMIDE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; NABILONE; NABIXIMOLS; NIFEDIPINE; O 1918; PARECOXIB; PENTOBARBITAL; RIMONABANT; UNCLASSIFIED DRUG; UNINDEXED DRUG; URB 297; URETHAN; VANILLOID RECEPTOR 1 ANTAGONIST;

ADRENERGIC SYSTEM; BEZOLD JARISCH REFLEX; BLOOD PRESSURE; BRADYCARDIA; CANNABIS SMOKING; CORONARY ARTERY BLOOD FLOW; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; DRUG STRUCTURE; DRUG USE; ELECTROSTIMULATION; EXCITATION AND STIMULATION; HEART HEMODYNAMICS; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; HEART PROTECTION; HEART RATE; HUMAN; HYPERTENSION; HYPOTENSION; NEUROTRANSMITTER RELEASE; NONHUMAN; PERFUSION PRESSURE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTSYNAPTIC INHIBITION; PRESSOR RESPONSE; PRESYNAPTIC INHIBITION; PRIORITY JOURNAL; RECEPTOR BINDING; REFLEX; REVIEW; SIDE EFFECT; TACHYCARDIA; VASODILATATION;

ANIMALS; ARACHIDONIC ACIDS; BLOOD PRESSURE; CANNABINOIDS; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; CARDIOVASCULAR SYSTEM; HUMANS; MODELS, CARDIOVASCULAR; POLYUNSATURATED ALKAMIDES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SPECIES SPECIFICITY; TRPV CATION CHANNELS;

EID: 84858204155     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01747.x     Document Type: Review

References (108)

1. 9-tetrahydrocannabinol in the rat. J Pharmacol Exp Ther 196: 649-656.
2. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
3. 1A receptors. Pharmacol Res 62: 228-236.
4. Aryana A, Williams M, (2007). Marijuana as a trigger of cardiovascular events: speculation or scientific certainty? Int J Cardiol 118: 141-144. (Pubitemid 46601644)
5. Baranowska U, Göthert M, Rudz R, Malinowska B, (2008). Methanandamide allosterically inhibits in vivo the function of peripheral nicotinic acetylcholine receptors containing the α7-subunit. J Pharmacol Exp Ther 326: 912-919.
6. Bátkai S, Pacher P, (2009). Endocannabinoids and cardiac contractile function: pathophysiological implications. Pharmacol Res 60: 99-106.
7. Bátkai S, Pacher P, Osei-Hyiaman D, Radaeva S, Liu J, Harvey-White J, et al,. (2004). Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 110: 1996-2002. (Pubitemid 39331913)
8. Benowitz NL, Jones RT, (1981). Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man. J Clin Pharmacol 21 (8-9 Suppl.): 214S-223S.
9. 9-tetrahydrocannabinol: autonomic nervous mechanisms. Clin Pharmacol Ther 25: 440-446. (Pubitemid 9164875)
10. Bilfinger TV, Salzet M, Fimiani C, Deutsch DG, Tramu G, Stefano GB, (1998). Pharmacological evidence for anandamide amidase in human cardiac and vascular tissues. Int J Cardiol 64 (Suppl. 1): S15-S22. (Pubitemid 28293460)
11. 1 receptors decrease contractile performance in human atrial muscle. J Cardiovasc Pharmacol 41: 657-664. (Pubitemid 36373805)
12. Brozoski DT, Dean C, Hopp FA, Hillard CJ, Segard JL, (2009). Differential endocannabinoid regulation of baroreflex-evked sympathoinhibition in normotensive versus hypertensive rats. Autonom Neurosci 150: 82-93.
13. Caldicott DGE, Holmes J, Roberts-Thomson KC, Mahar L, (2005). Keep off the grass: marijuana use and acute cardiovascular events. Eur J Emerg Med 12: 236-244.
14. Campagna JA, Carter C, (2003). Clinical relevance of the Bezold-Jarisch reflex. Anesthesiology 98: 1250-1260. (Pubitemid 36520214)
15. Carruba MO, Bondiolotti G, Picotti GB, Catteruccia N, Da Prada M, (1987). Effects of diethyl ether, halothane, ketamine and urethane on sympathetic activity in the rat. Eur J Pharmacol 134: 15-24. (Pubitemid 17015230)
16. Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafton J, Petersen-Zeitz KR, et al,. (2000). Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 288: 306-313. (Pubitemid 30226186)
17. Crawford WJ, Merritt JC, (1979). Effects of tetrahydrocannabinol on arterial and intraocular hypertension. Int J Clin Pharmacol Biopharm 17: 191-196. (Pubitemid 9162878)
18. Dean C, (2011). Endocannabinoid modulation of sympathetic and cardiovascular responses to acute stress in the periaqueductal gray of the rat. Am J Physiol Regul Integr Comp Physiol 300: R771-R779.
19. Di Marzo V, De Petrocellis L, Bisogno T, (2005). The biosynthesis, fate and pharmacological properties of endocannabinoids. Handb Exp Pharmacol 168: 147-185.
20. Dumont GJ, Kramers C, Sweep FC, Touw DJ, vanHasselt JG, de Kam M, et al,. (2009). Cannabis coadministration potentiates the effects of 'ecstasy' on heart rate and temperature in humans. Clin Pharmacol Ther 86: 160-166.
21. 9- tetrahydrocannabinol to rhesus monkeys. J Pharmacol Exp Ther 216: 247-253. (Pubitemid 11130179)
22. 1 spinal receptors in urethane-anaesthetized rats. Naunyn Schmiedebergs Arch Pharmacol 368: 270-276. (Pubitemid 37372549)
23. García MC, Adler-Graschinsky E, Celuch SM, (2009). Enhancement of the hypotensive effects of intrathecally injected endocannabinoids by the entourage compound palmitoylethanolamide. Eur J Pharmacol 610: 75-80.
24. Gardiner SM, March JE, Kemp PA, Bennett T, (2001). Regional haemodynamic responses to the cannabinoid agonist, WIN 55212-2, in conscious, normotensive rats, and in hypertensive, transgenic rats. Br J Pharmacol 33: 445-453. (Pubitemid 33027782)
25. Gardiner SM, March JE, Kemp PA, Bennett T, (2002a). Complex regional haemodynamic effects of anandamide in conscious rats. Br J Pharmacol 135: 1889-1896. (Pubitemid 34478300)
26. 1 receptor antagonist, AM 251, on the regional haemodynamic effects of WIN-55212-2 or HU 210 in conscious rats. Br J Pharmacol 136: 581-587. (Pubitemid 34717702)
27. Gardiner SM, March JE, Kemp PA, Bennett T, (2009). Factors influencing the regional haemodynamic responses to methanandamide and anandamide in conscious rats. Br J Pharmacol 158: 1143-1152.
28. Gash A, Karliner JS, Janowsky D, Lake CR, (1978). Effects of smoking marihuana on left ventricular performance and plasma norepinephrine: studies in normal men. Ann Intern Med 89: 448-452.
29. 3 receptor-mediated von Bezold-Jarisch reflex. Br J Pharmacol 138: 767-774. (Pubitemid 36390632)
30. Godlewski G, Alapafuja SO, Bátkai S, Nikas SP, Cinar R, Offertáler L, et al,. (2010). Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects. Chem Biol 17: 1256-1266.
31. Golech SA, McCarron RM, Chen Y, Bembry J, Lenz F, Mechoulam R, et al,. (2004). Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Res Mol Brain Res 132: 87-92. (Pubitemid 39531355)
32. Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, Huestis MA, (2006). The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers. Am Heart J 151: 754.e1-754.e5.
33. Gunthorpe MJ, Benham CD, Randall A, Davis JB, (2002). The diversity in the vanilloid (TRPV) receptor family of ion channels. Trends Pharmacol Sci 23: 183-191. (Pubitemid 34270601)
34. Hampson AJ, Bornheim LM, Scanziani M, Yost CS, Gray AT, Hansen BM, et al,. (1998). Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. J Neurochem 70: 671-676. (Pubitemid 28079356)
35. Ho WS, Gardiner SM, (2009). Acute hypertension reveals depressor and vasodilator effects of cannabinoids in conscious rats. Br J Pharmacol 156: 94-104.
36. Howlett AC, Reggio PH, Childers SR, Hampson RE, Ulloa NM, Deutsch DG, (2011). Endocannabinoid tone versus constitutive activity of cannabinoid receptors. Br J Pharmacol 163: 1329-1343.
37. Huang W, Rubinstein J, Prieto AR, Thang LV, Wang DH, (2009). Transient receptor potential vanilloid gene deletion exacerbates inflammation and atypical cardiac remodeling after myocardial infarction. Hypertension 53: 243-250.
38. Huestis MA, Boyd SJ, Heishman SJ, Preston KL, Bonnet D, Le Fur G, et al,. (2007). Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology (Berl) 194: 505-515. (Pubitemid 47492992)
39. Huitrõn-Reséndiz S, Gombart L, Cravatt BF, Henriksen SJ, (2001). Effect of oleamide on sleep and its relationship to blood pressure, body temperature, and locomotor activity. Exp Neurol 172: 235-243. (Pubitemid 33141169)
40. 1 receptors on peripheral sympathetic nerves. Br J Pharmacol 118: 2023-2028. (Pubitemid 26292572)
41. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R, (2009). Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30: 515-527.
42. Járai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, et al,. (1999). Cannabinoid-induced medenteric vasodilatation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A 96: 14136-14141.
43. Járai Z, Wagner JA, Goparaju SK, Wang L, Razdan RK, Sugiura T, et al,. (2000). Cardiovascular effects of 2-arachidonoyl glycerol in anesthetized mice. Hypertension 35: 679-684. (Pubitemid 30108168)
44. Jones RT, (2002). Cardiovascular system effects of marijuana. J Clin Pharmacol 42: 58-63.
45. Karschner EL, Darwin WD, McMahon RP, Liu F, Wright S, Goodwin RS, et al,. (2011). Subjective and physiological effects after controlled Sativex and oral THC administration. Clin Pharmacol Ther 89: 400-407.
46. Kase Y, Obata T, Okamoto Y, Iwai K, Saito K, Yokoyama K, et al,. (2008). Removal of 2-arachidonylglycerol by direct hemoperfusion therapy with polymyxin B immobilized fibers benefits patients with septic shock. Ther Apher Dial 12: 374-380.
47. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, et al,. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9: 76-81. (Pubitemid 36098263)
48. Kozłowska H, Baranowska M, Schlicker E, Kozłowski M, Laudański J, Malinowska B, (2007). Identification of the vasodilatory endothelial cannabinoid receptor in the human pulmonary artery. J Hypertens 25: 2240-2248. (Pubitemid 47537917)
49. Kozłowska H, Baranowska M, Schlicker E, Kozłowski M, Laudański J, Malinowska B, (2008). Virodhamine relaxes the human pulmonary artery through the endothelial cannabinoid receptor and indirectly through a COX product. Br J Pharmacol 155: 1034-1042.
50. Kurz C, Baranowska U, Lupiński S, Göthert M, Malinowska B, Schlicker E, (2009). Urethane, but not pentobarbitone, attenuates presynaptic receptor function in rats: a contribution to the choice of anaesthetic. Br J Pharmacol 157: 1474-1482.
51. 1 receptor. J Physiol Pharmacol 59: 3-15. (Pubitemid 351520158)
52. Kwolek G, Zakrzeska A, Schlicker E, Göthert M, Godlewski G, Malinowska B, (2005). Central and peripheral components of the pressor effect of anandamide in urethane-anaesthetized rats. Br J Pharmacol 145: 567-675.
53. 1-like cannabinoid receptors. J Pharmacol Exp Ther 281: 1030-1037. (Pubitemid 27258357)
54. Lake KD, Martin BR, Kunos G, Varga K, (1997b). Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Hypertension 29: 1204-1210. (Pubitemid 27198232)
55. 1 receptor knockout mice. Science 283: 401-404.
56. 9-THC. Drug Alcohol Depend 116: 86-92.
57. Liu J, Gao B, Mirshahi F, Sanyal AJ, Khanolkar AD, Makriyannis A, et al,. (2000). Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 346: 835-840. (Pubitemid 30171048)
58. 3 receptor-mediated Bezold-Jarisch reflex in rats. Pharmacol Rep (in press).
59. 1 receptor-mediated inhibition of the neurogenic vasopressor response in the pithed rat. Naunyn Schmiedebergs Arch Pharmacol 356: 197-202. (Pubitemid 27341974)
60. 1 receptor-mediated changes in heart rate and blood pressure in anaesthetized rats. Naunyn Schmiedebergs Arch Pharmacol 364: 562-569. (Pubitemid 33145097)
61. 1 receptors. Naunyn Schmiedebergs Arch Pharmacol 364: 233-241. (Pubitemid 32802152)
62. Malinowska B, Śupiński S, Godlewski G, Baranowska U, Schlicker E, (2008). Role of endocannabinoids in cardiovascular shock. J Physiol Pharmacol 59 (Suppl. 8): 91-107.
63. 2 receptors in the pressor effect of anandamide in rats. Naunyn Schmiedebergs Arch Pharmacol 381: 349-360.
64. Mathew RJ, Wilson WH, Davir R, (2003). Postural syncope after marijuana: a transcranial Doppler study of the hemodynamics. Pharmacol Biochem Behav 75: 309-318. (Pubitemid 36859816)
65. Mendizábal VE, Adler-Graschinsky E, (2007). Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. Br J Pharmacol 151: 427-440. (Pubitemid 46905012)
66. Mittleman MA, Rebecca AL, Maclure M, Sherwood JB, Muller JE, (2001). Triggering myocardial infarction by marijuana. Circulation 103: 2805-2809. (Pubitemid 32550068)
67. Molderings GJ, Likungu J, Göthert M, (1999). Presynaptic cannabinoid and imidazoline receptors in the human heart and their potential relationship. Naunyn Schmiedebergs Arch Pharmacol 360: 157-164. (Pubitemid 29420020)
68. Mukamal KJ, Maclure M, Muller JE, Mittleman MA, (2008). An exploratory prospective study of marijuana use and mortality following acute myocardial infarction. Am Heart J 155: 465-470.
69. 2+ modulation of glycinergic synaptic currents in rodent hypoglossal motoneurones. J Physiol 569: 817-831. (Pubitemid 41830225)
70. Niederhoffer N, Szabo B, (1999). Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation. Br J Pharmacol 126: 457-466. (Pubitemid 29057597)
71. Niederhoffer N, Szabo B, (2000). Cannabinoid cause central sympathoexcitation and bradycardia in rabbits. J Pharmacol Exp Ther 294: 707-713. (Pubitemid 30490848)
72. Niederhoffer N, Hansen HH, Fernandez-Ruiz JJ, Szabo B, (2001). Effects of cannabinoids on adrenaline release from adrenal medullary cells. Br J Pharmacol 134: 1319-1327. (Pubitemid 33097263)
73. Niederhoffer N, Schmid K, Szabo B, (2003). The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression. Naunyn Schmiedebergs Arch Pharmacol 367: 434-443. (Pubitemid 36718294)
74. 9-tetrahydrocannabinol in rats made hypertensive by chronic inhibition of nitric-oxide synthase. J Pharmacol Exp Ther 321: 663-672. (Pubitemid 46624493)
75. Offertáler L, Mo FM, Bátkai S, Liu J, Begg M, Razdan RK, et al,. (2003). Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol 63: 699-705. (Pubitemid 36297343)
76. 7 nicotinic acetylcholine receptor-mediated responses in Xenopus oocytes. J Pharmacol Exp Ther 306: 1003-1010. (Pubitemid 37025307)
77. 7- nicotinic acetylcholine receptor-mediated responses in Xenopus oocytes. J Pharmacol Exp Ther 310: 1152-1160. (Pubitemid 39108937)
78. Pacher P, Bátkai S, Kunos G, (2004). Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice. J Physiol 558: 647-657. (Pubitemid 39117608)
79. Pacher P, Bátkai S, Kunos G, (2005). Cardiovascular pharmacology of cannabinoids. Handb Exp Pharmacol 168: 599-625.
80. Pacher P, Bátkai S, Kunos G, (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58: 389-462. (Pubitemid 44394908)
81. Padley JR, Li Q, Pilowsky PM, Goodchild AK, (2003). Cannabinoid receptor activation in the rostral ventrolateral medulla oblongata evokes cardiorespiratory effects in anaesthetized rats. Br J Pharmacol 140: 384-394. (Pubitemid 37249199)
82. Pan HL, Chen SR, (2004). Sensing tissue ischemia. Another new function for capsaicin receptors? Circulation 110: 1826-1831.
83. Pertwee RG, (2005). Pharmacological actions of cannabinoids. Handb Exp Pharmacol 168: 1-51.
84. 2. Pharmacol Rev 62: 588-631.
85. Pfitzer T, Niederhoffer N, Szabo B, (2004). Central effects oft he cannabinoid receptor agonist WIN55212-2 on respiratory and cardiovascular regulation in anaesthetized rats. Br J Pharmacol 142: 943-952. (Pubitemid 39037044)
86. Rademacher DJ, Patel S, Hopp S, Dean C, Hillard CJ, Seagard JL, (2003). Microinjection of a cannabinoid antagonist into the NTS increases baroreflex duration in dogs. Am J Physiol Heart Circ Physiol 284: H1570-H1576. (Pubitemid 36460768)
87. 2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration. Br J Pharmacol 153: 347-357.
88. Randall MD, Kendall DA, O'SulliVan S, (2004). The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol 142: 20-26. (Pubitemid 38698188)
89. Russo E, Guy GW, (2006). A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66: 234-246. (Pubitemid 41773895)
90. 1 receptor-mediated inhibition of noradrenaline release in guinea-pig vessels, but not in rat and mouse aorta. Naunyn Schmiedebergs Arch Pharmacol 372: 139-146. (Pubitemid 41504161)
91. Sidney Y, (2002). Cardiovascular consequences of marijuana use. J Clin Pharmacol 42 (11 Suppl.): 64S-70S.
92. Singh NN, Pan Y, Muengtaweeponsa S, Geller TJ, Cruz-Flores S, (2011). Cannabis-related stroke: case series and review of literature. J Stroke Cerebrovasc Dis. Epub ahead of print.
93. Smith PJ, McQueen DS, (2001). Anandamide induces cardiovascular and respiratory reflexes via vasosensory nerves in the anaesthetized rat. Br J Pharmacol 134: 655-663. (Pubitemid 32977911)
94. Stefano GB, Bilfinger TV, Rialas CM, Deutsch DG, (2000). 2-arachidonyl-glycerol stimulates nitric oxide release from human immune and vascular tissues and invertebrate immunocytes by cannabinoid receptor 1. Pharmacol Res 42: 317-322.
95. 1 receptor mRNA in human vascular cells: is 2-arachidonoylglycerol a possible vasomodulator? Biochem Biophys Res Commun 243: 838-843. (Pubitemid 28414169)
96. Szabo B, Nordheim U, Niederhoffer N, (2001). Effects of cannabinoids on sympathetic and parasympathetic neuroeffector transmission in the rabbit heart. J Pharmacol Exp Ther 297: 819-826. (Pubitemid 32378017)
97. 1 cannabinoid receptor knockout mice. Handb Exp Pharmacol 168: 117-145.
98. 1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol 278: 279-283.
99. Varga K, Lake K, Huangfu D, Guyenet PG, Kunos G, (1996). Mechanism of hypotensive actio of anandamide in anesthetized rats. Hypertension 28: 682-686. (Pubitemid 26327969)
100. Varga K, Wagner JA, Bridgen DT, Kunos G, (1998). Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 12: 1035-1044. (Pubitemid 28359585)
101. Vidrio H, Sánches-Salvatori MA, Medina M, (1996). Cardiovascular effects of (-)-11-Δ8-tetrahydrocannabinol-dimethylheptyl in rats. J Cardiovasc Pharmacol 28: 332-336.
102. 1 receptors. Eur J Pharmacol 423: 203-210. (Pubitemid 32614159)
103. Wang Y, Wang DH, (2007). Increased depressor response to N-arachidonoyl-dopamine during high salt intake: role of the TRPV1 receptor. J Hypertens 25: 2426-2433. (Pubitemid 350060382)
104. Weis F, Beiras-Fernandez A, Kaczmarek I, Reichart B, Beiras A, Schelling G, et al,. (2010). Substantially altered expression of cannabinoid receptor 2 and activated endocannabinoid system in patients with severe heart failure. J Mol Cell Cardiol 48: 1187-1193.
105. 1 receptor. J Physiol 586: 835-845. (Pubitemid 351194121)
106. Zahner MR, Li DP, Chen SR, Pan HL, (2003). Cardiac vanilloid receptor 1-expressing afferent nerves and their role in the cardiogenic sympathetic reflex in rats. J Physiol 551: 515-523. (Pubitemid 37121709)
107. Zakrzeska A, Schlicker E, Baranowska M, Kozłowska H, Kwolek G, Malinowska B, (2010). A cannabinoid receptor, sensitive to O-1918, is involved in the delayed hypotension induced by anandamide in anaesthetized rats. Br J Pharmacol 160: 574-584.
108. Zuurman L, Ippel AE, Moin E, Van Gerven JM, (2009). Biomarkers for the effects of cannabis and THC in healthy volunteers. Br J Clin Pharmacol 67: 5-21.